Pipeline
A robust and nimble engine
We are leveraging our fundamental expertise in immunology and tumor biology to innovate and discover robust and safe TCRs directed against oncogenic and viral driver mutations.
Target
Discovery
IND Enabling
Clinical
Oncogenic Driver Programs
KRAS G12V
KRAS G12D
Mutant P53
Undisclosed
Viral Driver Programs
MCPyV
Undisclosed
